Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Smoldering Multiple Myeloma 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Kidney Neoplasms 1

Interventions

aldesleukin 24Cyclophosphamide 14Interferon-alpha 10fludarabine 8fludarabine phosphate 7Interleukin-2 6Chemotherapy, Adjuvant 6sargramostim 5Neoadjuvant Therapy 5Fluorouracil 4Vincristine 3Sunitinib 3Magnetic Resonance Spectroscopy 3Dactinomycin 3Carboplatin 3Bevacizumab 3Amplified Fragment Length Polymorphism Analysis 3vandetanib 2valspodar 2tanespimycin 2ixabepilone 2carboxyamido-triazole 2bryostatin 1 2Vinblastine 2Thalidomide 2Temozolomide 2Sorafenib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Muromonab-CD3 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Kidney Neoplasms × AH 111585 × Clear all
NCT01633255 2019-12-17

[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡